TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05696678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
Study: NCT05049941

Intervention type: DIAGNOSTIC_TEST
Intervention: lactat and blood gases
Description: observational

Intervention type: DIAGNOSTIC_TEST
Intervention: lactat and blood gases
Description: observational

Intervention type: DIAGNOSTIC_TEST
Intervention: lactat and blood gases
Description: observational
Study: NCT05316233

Intervention type: DEVICE
Group type: OTHER
Intervention: VOLITE XC
Description: Intradermal Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLITE XC
Description: Intradermal Injection

Intervention type: DEVICE
Group type: OTHER
Intervention: VOLITE XC
Description: Subdermal Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLITE XC
Description: Subdermal Injection
Study: NCT05031494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered at a dose of 240 mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered at a dose of 240 mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered at a dose of 240 mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administrated each 21-day cycle.
Study: NCT05926674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: Myofascial release is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch Contact
Description: The sham treatment of light touch will be applied to the lumbar spine and this form of contact is not therapeutic. It is only meant to only mimic a manual therapy technique.
Study: NCT06232187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence feedback for ultrasound EFW standard plane images
Description: AI feedback in two levels, in aid of the participants, to obtain the right standardplane images used in fetal ultrasound EFW calculation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence feedback for ultrasound EFW standard plane images
Description: AI feedback in two levels, in aid of the participants, to obtain the right standardplane images used in fetal ultrasound EFW calculation.
Study: NCT04767815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet A group
Description: Fasting + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet A group
Description: Fasting + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet A group
Description: Fasting + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet A group
Description: Fasting + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet A group
Description: Fasting + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet A group
Description: Fasting + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet B group
Description: 30 minutes after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet B group
Description: 30 minutes after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet B group
Description: 30 minutes after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet B group
Description: 30 minutes after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet B group
Description: 30 minutes after a high-fat meal + DWN12088 200 mg
Study: NCT05512195

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: New delineation approach
Description: New delineation approach
Study: NCT06131294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Application (Experimental Fluoride Application)
Description: Fluoride containing applications are applied on white spot lesions. First solution was air-dried before the second application with the other component was done.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluor Protector S
Description: Fluor Protector S is applied on white spot lesions.
Study: NCT06482801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks.
Study: NCT04767815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet B group
Description: 30 minutes after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet C group
Description: 2 hours after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet C group
Description: 2 hours after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet C group
Description: 2 hours after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet C group
Description: 2 hours after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet C group
Description: 2 hours after a high-fat meal + DWN12088 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet C group
Description: 2 hours after a high-fat meal + DWN12088 200 mg
Study: NCT05155358

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood test
Description: Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood test
Description: Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood test
Description: Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
Study: NCT04649645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOBACCO CIGARETTES
Description: Participants in Arm A will continue smoking their own cigarette brand as usual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)
Description: Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NOT SMOKING
Description: Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
Study: NCT06482801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks.
Study: NCT06498947

Intervention type: OTHER
Intervention: This study was observational with no intervention.
Description: This study was observational with no intervention.

Intervention type: OTHER
Intervention: This study was observational with no intervention.
Description: This study was observational with no intervention.

Intervention type: OTHER
Intervention: This study was observational with no intervention.
Description: This study was observational with no intervention.
Study: NCT05609240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: See arm/group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: See arm/group description
Study: NCT06015685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embedded Clinic
Description: Once a week, a Primary Care clinic half-day will be dedicated to multi-disciplinary, team-based DM care. The inter-professional team will include an Internal Medicine attending physician, an Internal Medicine resident, a DM educator, a nurse trained in professional CGM, a behavioral health provider, and a social worker to assist in finding resources for housing, food, and patient assistance programs.
Study: NCT01970111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, High dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, Low dose
Study: NCT05901168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Video Games Intervention
Description: Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
Study: NCT06015685

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: Researchers will use a 2:1 ratio of control to intervention patients. Using the CDW, researchers will identify a control population \[patients who receive routine care (i.e., referral to subspecialty care)\], who will be a propensity-matched cohort of individuals with similar age, gender, race/ethnicity, zip codes, insurance type, visit dates, and co-morbidities (Charlson Comorbidity Index) as the intervention group.
Study: NCT05901168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise Intervention
Description: Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes.
Study: NCT05684315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue flossing therapy
Description: BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
Study: NCT05248022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-eluting beads bronchial arterial chemoembolization
Description: Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days.
Study: NCT05231694

Intervention type: DRUG
Group type: OTHER
Intervention: Nerver growth factor (NGF) injection
Description: The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.

Intervention type: DRUG
Group type: OTHER
Intervention: Nerver growth factor (NGF) injection
Description: The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo injection
Description: The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
Study: NCT06429163

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of the anterior abdominal wall
Description: Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infiltration of the anterior abdominal wall
Description: Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper hypogastric plexus blockade
Description: At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Upper hypogastric plexus blockade
Description: At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.
Study: NCT06333522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
Study: NCT06461455

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal for astigmatism contact lenses
Description: Investigational multifocal contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal for astigmatism contact lenses
Description: Investigational multifocal contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A multifocal for astigmatism contact lenses
Description: Commercially available multifocal contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A multifocal for astigmatism contact lenses
Description: Commercially available multifocal contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfection system

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfection system
Study: NCT05388123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose vemurafenib plus rituximab
Description: Vemurafenib 240 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib
Study: NCT05231265

Intervention type: OTHER
Intervention: Walking task
Description: Treadmill walking task with study of fractal variability (complexity) for 10 minutes.
Study: NCT06022965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive SOC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Complete CARG-GA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Geriatric Assessment
Description: Complete CARG-GA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies